VisionTech Partners

Tag: Ben Pidgeon

  • Meet November Pitch Presenter #2: John Stachowiak, React Mobile

    Meet November Pitch Presenter #2: John Stachowiak, React Mobile

    Seattle-based React Mobile is a VisionTech Angels portfolio company with a workforce safety platform with solid traction in the hospitality industry. Our group initially invested in 2019. A lot has changed since then with new leadership and a new release of their solution. React Mobile is now raising a convertible round. Based on the company’s progress, VisionTech Angels investors have expressed $100,000 in soft interest prior to the formal pitch on Thursday, November 18. I recently sat down with CEO John Stachowiak and here’s our discussion.

    BP: Tell me about yourself and other leadership changes. I hear you have an Indiana connection.
    JS: I do! I am a proud Indiana University graduate. I’ve been on the React Mobile board of directors since mid 2018. During the pandemic, the board agreed that we needed to upgrade the leadership team with more seasoned members. The first change was replacing the CTO in December 2020. Riley Eller had worked with me at my last company for 10 years. He is without question the most talented CTO and strategic business thinker I have ever worked with. We also replaced the CFO position. I accepted the CEO position this year. This is my fourth time as a CEO, having led companies in the United States and Europe. My experience has been with early growth startups, and I’ve taken three companies to exit with returns of 8x, 13x and 26x respectively. I believe my experience and skills match up very well as React Mobile enters its growth phase.

    BP: Any changes in your product offering, technology, or business model?
    JS:  This year we unveiled version 2.0 of our workplace safety platform. It’s designed to deliver the highest panic button reliability and beacon location accuracy on the market while being radically simpler for hotel workers to use. We’ve also simplified our SaaS pricing. Here are some of the new features:

    • A new responder application that enables employees to receive safety alert notifications on their mobile devices and dispatch help. Management receives analytics measuring how long it took for an employee to respond to an active alert.
    • Support for all third-party iBeacons such as Aruba, Cisco Meraki and CommScope/RUCKUS®. With iBeacon functionality already existing in a hotel’s WIFI access points, hoteliers will save up to 80% of workforce safety platform install costs.
    • A double-redundant alert pipeline to ensure that alerts are dispatched from panic buttons to responders in the fastest time possible. React Mobile 2.0 delivers 99.9% of alerts in less than a half-second.
    • Two-way, multi-lingual conversations in English, Spanish, Tagalog, French, and Chinese. Any language can be supported on request.

    There are other important enhancements which I’ll share in my pitch.

    BP: What impact did COVID have on hospitality industry and React Mobile’s business? 
    JS: The pandemic has had a devastating effect on the hospitality industry, particularly in the early days when travel ground to a halt. Once areas of the country started to regain a sense of normalcy, the industry focused on adjusting processes and regaining their footing. Some areas around the country have rebounded significantly, which is welcome to all of us. In terms of React Mobile, 2020 and 2021 were both growth years. Our SaaS revenue grew more than 100% in 2020 over 2019 and is on track to grow 100% in 2021 over 2020. The number of installed properties grew by 133% in 2020 and in 2021, we’re up 48% to date.

    BP: That’s impressive given all of the disruptions of COVID and now the labor shortage. What do you attribute that to?
    JS: There are a couple of factors. Employee safety continues to be the number one driver. What’s shocking to me personally is 58% of hotel workers report being assaulted on the job. And 96% of housekeepers say they’d feel safer with a panic button. Leading brands  representing 23,000 hotels have signed the “Five Star Promise” committing their organizations to employee safety devices. Compliance must be met by the end of 2022. At the same time, the number of states mandating panic buttons in hotels with more than 50 rooms is increasing.

    As a result, demand is strong. We’ve signed 12 Master Service Agreement with major brands that represent 23,000 properties. Of these, about 25% – 5,729 properties – are exclusive agreements. The growth potential for React Mobile is huge.

    BP: Any other big wins?
    JS: We have a strong and growing presence in Las Vegas. Fourteen of the 30 major properties on the strip are React Mobile customers. We are currently covering 37,791 of the 93,022 rooms on the Las Vegas strip.

    BP: Now that the platform is proven, are you looking at other industries?
    JS: Absolutely. Education is a natural one for React Mobile. Looking at elementary, middle and high schools, as well as colleges and universities, we’re looking at a total addressable market of $490 million. There is definitely recognition for the need for improved security methods. We’re also looking at health care. Hospitals represent a total addressable market of $210 billion. A key strategic investor in React Mobile is a respected technology provider in these industries and has provided clear guidance for adapting our technology stack to better serve them.

    BP: How much are you raising and what will the proceeds be used for?
    JS: We are looking to raise up to $3 million with the same terms as our last convertible note. These funds will allow us to continue to scale the company.

    BP: Why should VisionTech Angels invest another round in React Mobile?
    JS: Despite COVID-19, our SaaS revenue will end the year at an ARR of approximately $2.4 million with a pre-money value of about $13.5 million, a multiple of less than 6x. Our new 2.0 product release is the best in the industry and with it, we expect to grow revenue another 100% in 2022 and again in 2023. At this point, we have our workplace safety platform where it needs to be, and in addition to expanding our beachhead in the hospitality industry, we are looking at new opportunities in education and health care. Bottom line, we would like VisionTech Angels to continue to grow with us.

    To learn more about React Mobile, visit their website. VisionTech Angels’ November Pitch Events will be virtual on Thursday, November 18 at Noon ET and at 6 p.m. ET. Pitch events are open to our members and accredited investors interested in joining our group. To register, check your email for an invitation, go to our Events page or email Ben Pidgeon at bpidgeon@visiontech-partners.com.

  • Meet November Pitch Presenter #1: Adam Steege, Trio Labs

    Meet November Pitch Presenter #1: Adam Steege, Trio Labs

    I was introduced to Adam Steege, founder, president and chief technology officer of Trio Labs, by another investor in the angel space, John Lilly. He is impressed with the company’s novel imaging technology and materials manipulation techniques that enable rapid, high-precision, additive manufacturing of micro parts needed in medical devices. Given our group’s interest in life sciences startups and expertise in the medical device industry, I invited Adam to present to VisionTech’s Screening Committee. We were also impressed by Trio Labs’ technology and traction and agreed he should present at our November Pitch Events. Here’s a sneak  preview.

    BP: Tell me about how Trio Labs came to be.
    AS: I’m a serial entrepreneur and inventor. One of my previous companies was Agile Endo-surgery that developed articulated surgical instruments to expand the scope of minimally invasive surgery. During my six years with Agile, I really took a deep dive into medtech and more importantly, surgical trends pointing to the need for better, more cost-effective options for micro manufacturing on a millimeter scale. I recognized an opportunity to leverage metal additive manufacturing processes at the desired resolution of five microns, but do it at a high-volume manufacturing scale, something no one else was doing. Trio Labs uses its own technology to produce these miniaturized parts using ultra high-resolution 3D printing of metals. The manufacturing process is different. What’s also different is that we’re selling parts, not 3D printers.

    BP: What pain points did you see in the medical device market that you are solving?
    AS: Medtech is demanding miniaturization for surgical instruments and hollow microneedles to meet clinical demands. Here’s an example: vascular surgeries where the surgeon needs to deploy a valve in a heart procedure and a lot of small components are required to enable this mechanism. Other technologies can’t address this size. Here’s another example: the surgeon has to pull a clot in a stroke patient in blood vessels smaller than 1mm. Small parts make this type of life-saving instrumentation possible. The reality of human anatomy versus existing technology causes a significant pain point. With our ability to create micro parts with precision and manufacture at high volume will solve a lot of industry—and patient—pain.

    BP: Additive manufacturing has been around for a while. Manufacturing at scale has been the challenge. What’s your value proposition?
    AS: Frankly, our ability to scale manufacturing beyond prototyping is a large part of our value proposition. Couple that with the fact that we’re making high throughput micro manufacturing possible for the first time is significant. Innovators within the medical device and micro needle spaces looks at that and their eyes get big as it opens up so many doors to future innovation. In that respect, Trio Labs’ ability to produce micro components with exacting precision and in desired volumes makes us unique and a powerful partner.

    BP: How large is the market? What are your priorities in terms of market segments?
    AS: Globally, it’s a multi-billion market. We’ve identified several segments. First, minimally invasive surgical devices which has a total addressable market of $50 billion. The next largest segment is microneedles used for pain-free drug delivery and diagnostics. This includes auto injectors, infusion systems and blood sampling devices. Globally, this represents a $20 billion market. Diabetes care is a sub-segment of the microneedle application space. It represents a $5 billion market in the U.S. alone. Diabetes is a global issue so this is the tip of the iceberg.

    Trio Labs surgery

    BP: What’s your traction like thus far?
    AS: We have nine customers, many of them household names, with strong interest. They have sent us design files to begin working on. Our model is to acquire customers are the R&D stage and support development. This way our micro parts are specified in the device and support volume production. With all of the innovation in minimally invasive surgical devices as well as in other areas, we believe this approach is sound. We expect to start generating revenue before the end of this year.

    BP: What kind of IP protection do you have?
    AS: Our goal is to have a massive IP portfolio all of which we will own. We are currently working on global patents in 10 jurisdictions. These include our core process and provisional patents. When we’re done, we will have a few hundred patents, which will support our exit strategy.

    BP: What does the competitive landscape look like?
    AS: Micro manufacturing is very difficult to do and do well and that limits competition. However, there are options to Trio Labs: metal injection molding, CNC machining and electrochemical manufacturing. Each has its own set of limitations like cost, speed or lack thereof, and inability to meet the very precise micro specifications at scale. Trio Labs has proven our technology and we can produce at scale at very attractive margins, giving us a competitive advantage over these traditional manufacturing methods.

    BP: This is a $6 million Series A and you’ve raised $5.5M. Who are the other investors? What will the proceeds be used for?
    AS: We’ve gotten excellent support for our Series A so far. Two of our board members have personally invested, and we’ve also gotten support from VentureSouth and the Harvard Business School Alumni Angels Association. We hope to add VisionTech to our cap table.

    In terms of use of funds, we intend to build out our manufacturing infrastructure in 2022. Also, our Series A gives us the runway to continue developing strategic partnerships and ramping up the development projects in our pipeline.

    BP: What’s your exit  potential?
    AS: We believe we will have a number of options, one of which is to be acquired by a larger medical device company that will seize the opportunity to control the micro manufacturing space. Another option is to go the IPO route.

    BP: Why should VisionTech Angels invest in Trio Labs?
    AS: Trio Labs is truly defining a new space in the medical device industry and as minimally invasive surgical procedures have become the norm, the demand for smaller devices and miniaturized parts has grown exponentially. We have the technology, processes, and ability to scale to meet this demand. Our leadership and advisory team are truly impressive. Among our advisors is Bill Hawkins, former CEO of Medtronic, and Stephen Nigro, former president of 3D Printing at HP. Bill, Stephen, and our other advisors are actively involved in our strategy and day-to-day operations. Finally, the impact we can make on patients’ lives and potential financial return for investors will be significant.

    To learn more about Trio Labs, visit their website. VisionTech Angels’ November Pitch Events will be virtual on Thursday, November 18 at Noon ET and at 6 p.m. ET. Pitch events are open to our members and accredited investors interested in joining our group. To register, check your email for an invitation, go to our Events page or email Ben Pidgeon at bpidgeon@visiontech-partners.com.

  • Clean Ingredients for a Healthier World: Meet Joanne Zhang of Flourring, October Pitch Presenter #1

    Clean Ingredients for a Healthier World: Meet Joanne Zhang of Flourring, October Pitch Presenter #1

    I can’t exactly remember when I met Joanne Zhang, but I’ve always been impressed with her professionalism. We reconnected at this year’s Innovation Showcase. I’m on the board of the Showcase sponsor, The Venture Club of Indiana, and met all of the startups nominated for the pitch competition. One of the finalists was Joanne, who is the CEO and co-founder of Flourring. Flourring was definitely the “sleeper” of The Innovation Showcase. It wasn’t an app, its financial model wasn’t SaaS, and it’s unlikely to inspire tech geeks. What Flourring does have is a huge market and consumers clamoring for its products. Not by name, but for the benefit of making many of the foods and beverages we eat everyday more natural, clean and healthy. I invited Joanne to present to VisionTech’s Screening Committee, and we all agreed she and Flourring should present at our October Pitch Events. Here’s a sneak  preview.

    BP: Tell me about your professional career before becoming an entrepreneur.
    JZ: My career track is very different than many entrepreneurs. I spent 20 years in the corporate world, including 14 years at Praxair and a year with Danisco, an ingredients company. Over the course of my corporate career I worked in marketing, procurement and supply chain, and finance. At Praxair, I was in charge of finances for a $200 million business unit. I’m grateful for my time in corporate because it created a strong foundation for my own startup company. I know how and where to avoid mistakes and have been able to run the company professionally from the start.

    BP: How did Flourring come to be?
    JZ: Flourring started as a part of Phytoption LLC, a Purdue innovation startup company I co-founded. We had an SBIR award from the National Science Foundation to develop ingredients for drug, food, cosmetics, and agriculture. During that project, we have developed clean and functional ingredients applicable to the food and beverage industries. So we plan to use Flourring to focus on commercializing FLOURA™, a series of all natural, functional flours that could replace traditional emulsifiers and texturizers, many of which are artificial. Traditional emulsifiers, while present in many, many processed or restaurant foods, are usually not natural ingredients and are heavily processed themselves.

    BP: What pain points did you identify in the market and how are you solving them?
    JZ: There are two big pain points: Consumers’ demand for cleaner, more natural foods and food producers’ needs for a natural alternative to traditional emulsifiers that works for their products. Our proprietary natural flours solves both.

    Natural and organic foods have been around and very popular with a segment of the population for a long time, but it’s only been recent years that the general consumer population has begun looking for and requesting more natural ingredients. As a mother myself, I had trouble finding healthy snacks for my own child that didn’t contain artificial additives. So there is now a growing “clean label” movement among consumers who are questioning the additives in foods and basing their purchases on what’s on a product’s label.

    Consumer packaged goods (CPGs) companies see what consumers want but up until now there were hardly any feasible substitutes for traditional chemical surfactants, gums, or other types of unwanted emulsifiers and stabilizers. And they can’t just remove them as emulsifiers are needed to prevent separation of ingredients, create a smooth texture and extend shelf life. As an example, a liquid coffee creamer would have separate layers, if they took out the emulsifier. Can you imagine how unappealing it is? With FLOURA™, we’re providing a single ingredient option that’s non-GMO, gluten free, all natural, and doesn’t require chemicals to produce it, and works for a variety of food and beverage, supplements, and even some personal care products.

    BP: What’s the FLOURA™ product range look like?
    JZ: We currently have several types of flours under the FLOURA™ brand that address the specific requirements of plant milks, creamers, shakes, and smoothies; sauces, soups, and salad dressings; bakery items such as cakes and tortillas; nutraceuticals like hemp oils and essential oils; frozen desserts like ice creams and ice cream novelties; and finally, natural lotions and creams for personal care. In each of these categories, FLOURA™ helps ensure the stability and texture with desirable natural ingredient for a cleaner ingredients label.

    BP: What’s your traction like thus far?
    JZ: We are building our customer pipeline, and have signed letters of intent from two customers, one in the U.S. and the other in Europe. Both were looking for natural alternatives to current emulsifiers and found Flourring.

    BP: How big is the market?
    JZ: The ingredients market in the United States, Europe and Asia is huge. The overall global emulsifier market is estimated at $8.4 billion (USD), along with another $12 billion for stabilizers or texturizers. If that surprises you, consider this: emulsifiers and texturizers are used in a wide range of not just food and beverage products but also personal care, pharmaceuticals and even industrial applications. Flourring is targeting is clean label products, a market projected to reach $51.1 billion (USD) by 2024. Consumers are driving growth in this segment. More than 90% of U.S. consumers believe food and beverage options with recognizable ingredients are healthier. Beyond this, the market is attractive because of the spend of individual companies, which can range from a hundred thousand a year to a couple of million dollars.

    BP: What’s your exit  potential?
    JZ: Very straightforward. There are only a few large players in the ingredients market and they’re watching the trend of clean labels, which has accelerated with COVID-19. Some have already been in contact with us.

    BP: Are you required to have FDA approval on your products?
    JZ: No, our ingredients are natural—corn, rice—so FDA approval is not required. We have gone through a legal review by one of the largest legal firms for the food industry to determine the labeling, and the conclusion was that FLOURA™ is labeled as a flour such as rice flour or corn flour.

    BP: Do you have any IP protection?
    JZ: I’m very proud of our IP protection. We have a lot of experience with patents so securing a worldwide patent for our process was a priority. That patent was filed in 2018 and is pending in many countries or regions worldwide. Ultimately, we’ll have several patents broken down from the initial filing that will protect our products and technology from different angles, which include materials, processing, and applications.

    BP: Do you have competitors beyond traditional emulsifiers?
    JZ: Our natural functional flours are the first of their kind emulsifiers on the market so no, we don’t currently have competitors other than the additives such as modified starches, gums, and synthetic chemicals we want to replace.

    BP: How much are you planning to raise and how will the proceeds be used?
    JZ: We are raising a $1 million seed round, of which we already have $800,000 committed. Half of the funds will be used to scale our manufacturing and the other half will fund our 2022 runway. We have a vice president of sales and will build a production team after the round is closed.

    BP:  Why should VisionTech Angels invest in Flourring?
    JZ: There are three very compelling reasons to invest in Flourring. The clean ingredients market is predicted to enjoy high growth for the foreseeable future. Consumers are communicating their preference for natural ingredients and CPGs are responding where they can. Flourring provides new options that can enable CPGs to meet consumer demand. Second, this is a low-risk opportunity. We have established our products and processes. Now, it’s time to scale, which is what this raise is about. Finally, cost will not be a barrier to market entry. Our products are priced at or below competing products. Too, our gross margins are high, about 75% at scale, because the costs of our raw materials are low.

    To learn more about Flourring, visit their website. VisionTech Angels’ October Pitch Events will be virtual on Thursday, October 28 at Noon ET and at 6 p.m. ET. Pitch events are open to our members and accredited investors interested in joining our group. To register, check your email for an invitation, go to our Events page or email Ben Pidgeon at bpidgeon@visiontech-partners.com.

  • Meet VisionTech Angels’ August Pitch Presenter #2: GeoH

    Meet VisionTech Angels’ August Pitch Presenter #2: GeoH

    I was introduced to Doug Rowe and Dylan Vester, co-founders of GeoH, by Oscar Moralez, VisionTech’s managing director. He had worked with Doug years ago when still at Biostorage. After learning more about GeoH’s solution for the home health industry, Oscar referred them to me and I was immediately impressed. Doug owns a home care company, and he understands the pain and inefficiency of an industry still reliant on paper for billing and payroll. Three years ago, he and Dylan set out to provide a cloud-based alternative. Fast forward, and their traction is impressive. Both are running hard and enjoying every minute, so the VisionTech Angels Screening Committee invited them to pitch. Here’s a sneak preview. I hope you’ll join us to hear Doug and Dylan during our August Pitch events on the 24th and 26th of this month. 

    • VisionTech’s Ben Pidgeon

    BP: Many founders have a personal passion behind their company. What’s the back story on GeoH?
    DR: I started a home care company in Indiana four years ago, and the business grew fast. The only problem was that everything about the business was paper based, from how caregivers tracked their patient visits to billing and payroll. Total and complete nightmare. I wanted an app  to solve the problems I was facing in the business, so I called my now co-founder Dylan Vester. We worked to make something that not only solved the problems I was facing in the home care space, but was built on bleeding-edge cloud technology so iterations and features can be easily added. As of today, we provide online scheduling, billing, payroll, reporting and analytics, user management, and notifications. Because of changes in the industry brought on by regulations and laws like the Cures Act and market events like COVID, we are constantly evolving and enhancing our platform to meet current and new pain points.

    BP: What pain point are you solving with GeoH?
    DR: The home health industry is primarily owned by small independent agency owners/operators. Some of them have been in the business for decades, and many still use paper forms as a tracking mechanism. It’s an issue because they have to save paperwork for seven years. If you have a larger operation, you have a warehouse full of old documents. Outside of the obvious administrative burdens we relieve as a digital solution, we also satisfy the 2016 Cures Act for Electronic Visit Verification (EVV). We make running an agency more efficient while simultaneously keeping agencies compliant.

    BP: When did you launch and what kind of traction are you getting to date?
    DR: We launched the company in 2017, spent a year in development, and began selling in 2019. We’ve been adding users and caregivers ever since. We’re now in 11 states with aggregators, with 130 agencies, plus more than 3,000 users and counting. I give a lot of credit to Dylan for our traction. The product, our user interface, and user experience drive agencies to us from other software solutions.

    DV: (smiles) I spent a lot of time on the user experience. Before this, I worked with Salesforce and Microsoft, and I’ve applied much of the same sophisticated backend computing and automation you find in their products. We may be a small company, but our platform and app are very sophisticated and work well.

    BP: What benefit is most appreciated by customers?
    DV: Our customers are not typically computer savvy, so we’ve designed the platform and the app to be super simple and intuitive to use. We can have new clients live in five minutes. There is not a long, steep learning curve to work in the solution from a functional side. People understand the platform and workflows immediately. Caregivers only have to go to one screen to document their visits. Again, super easy, intuitive, and they don’t have to spend time writing paper notes and turning them in. Their work notes go straight into the agency’s system.

    DR: As a home care agency owner myself, I like that we’ve made paper obsolete for operations like payroll. Our software tracks a caregiver’s days, hours, and waiver code for each patient visit, making documenting patient visits so much easier for caregivers. GeoH has a  client with 14 locations and 1,000 caregivers. It would take him two days to do payroll because each caregiver’s hours, visits, and coding differed. So basically, it was like doing payroll 1,000 different ways. Because employees’ time and visits are captured digitally, go straight to the cloud, and because the process is automated, payroll takes under an hour. This owner has a $20 million business and by switching to GeoH, we’re saving him $1.2 million annually in reduced overhead. That would not have happened if he’d stayed with paper.

    BP: What’s your revenue model?
    DR: As a cloud-based, SaaS solution, it’s a user-based pricing model determined by the length of the contract. Two-year contracts are $10 per user; one-year contracts are $12 per user, and month-to-month is $15 per user. We have a 97% retention rate with clients and are very sticky regardless of their plan. Once we launch the skilled version (nursing, therapy), our monthly recurring revenue jumps 4x based on current clients and the additional cost of the new features while opening a new vertical.

    BP: Is GeoH unique in the market or do you have competitors?
    DR: There are many competitors out there with home health management software but nothing like GeoH. The short answer is our platform and app work. But here are some examples. We’re a standalone solution but we’ve completed critical integrations with state aggregators in 11 states, with more coming on shortly. We work with government agencies like the Indiana Department of Health, CMS, and ACHC to stay informed on regulations and upcoming changes to add those nuances to the software. This advantage garnered my agency’s perfect survey results with zero deficiencies and zero tags the past two times. We’re also integrated with managed care organizations. Our users love us and refer others to us weekly.

    DV: From a software perspective, our app is native unlike competitors’ apps so it opens up much like Facebook without requiring a webpage login. We work equally well on iOS, Android,  tablets, and PCs. The app is intuitive and the workflow mimics that of a home health agency. Additionally, our support for the software is second to none. Not only do we have a standard call in/email support system, but we also utilize newer technologies for faster response through SMS messages.

    We are now working on our next release that will include the initial patient assessment, 485 doctors’ orders and sending the transmission of data to Oasis in Texas, which is how Medicaid determines billing amounts by service. These are the feature sets required for the skilled side that do not already exist in our platform. This functionality is huge and as Doug mentioned, will significantly increase our monthly recurring revenue.

    BP: Is there any IP or patents that protect your market position?
    DV: We have trade secrets in the way the platform is built to manage large volumes of data, provide safety and security of information, and to massively scale as the business grows. Our algorithms also help streamline operations across multiple operating systems and allow us to integrate seamlessly with multiple external applications to provide robust business tools. Many competitors are attempting to do what we do; however, we’re using new, cloud-based technology that is synchronous, giving us a significant advantage over competitors.

    BP: How big is the market? How are you prioritizing your rollout?
    DR: With the aging population, the market is huge. There are three million caregivers In the United States and the industry is expected to add another 1.5 million by 2024. We’re targeting states with the highest amount of Medicaid dollars where we can grow the fastest.

    BP: How much are you planning to raise and what will the proceeds be used for?
    DR: This is a seed round and our goal is to raise $1.5 million. Funds will be used primarily on head count and adding more functionality. A big focus will be on the development team and  sales team as this is a one-on-one sales play.

    10) Why should VisionTech Angels invest in your company?
    DR: The home care industry faces a government mandate to be EVV compliant with charting, billing and payroll practices. No one wants to change but they have to, and ours is the only solution that’s easy to implements and ensures compliance. To put it in perspective, in Indiana alone there are 1,400 agencies that need to be compliant now. The opportunity is significant. We are well-positioned and believe VisionTech Angels will want to be a part of GeoH’s success.

    To learn more about GeoH, visit their website. VisionTech Angels’ August Pitch Events will be virtual on Tuesday, August 24 and Thursday, August  26 at 6 p.m. Pitch events are open to our members and accredited investors interested in joining our group. To register, check your email for an invitation, go to our Events page or email Ben Pidgeon at bpidgeon@visiontech-partners.com.

  • Meet August Pitch Presenter #1: Doug Wilcox, CEO of Safekeeping

    Meet August Pitch Presenter #1: Doug Wilcox, CEO of Safekeeping

    Many years ago when I was a Purdue student, I worked part-time at a local retirement and long-term care facility in West Lafayette. It was the “cream of the crop” in terms of quality of care and resident experience, but even then, I could see the constant demand by family members for information on loved ones and how this challenged staff. That said, staff also had information needs not always easy or immediate to satisfy. I first met Doug Wilcox, CEO of Safekeeping, at a VisionTech Angels Screening Committee meeting a few years back. Although we liked the business model, it was very early stage, so we passed. Time passed and when Doug pitched the committee a second time we said yes because of Safekeeping’s impressive traction and market trends that could accelerate adoption. We invited Safekeeping to present during our August Pitch Week. Here’s a sneak preview. I hope you’ll join us to hear Doug and participate in the discussion on this investment opportunity.

    BP:  There’s a good personal story behind the founding of Safekeeping. Do you mind sharing it?
    DW: Not at all. It’s kind of a two parter. My co-founder, Matt Prasek, started the company while a senior at Ball State University. His grandfather had a skiing accident that left him incapacitated and in nursing facilities for the rest of his life. Matt felt like he was constantly badgering his grandfather’s caregivers for updates so for his senior class project, he came up with a communications tool, which was named Best New Venture at Ball State. The second part is my own experience with my mother who spent the last 18 months of her life in a long-term care facility. I would have to drive two hours just to get questions answered about her care and condition. The facility gave me a flier on Safekeeping and intrigued, I reached out to Matt and joined him in 2017. At the time, Safekeeping had one customer, the facility where my mother lived.

    BP:  What pain points do you address with Safekeeping and the How’s Mom platform and app?
    DW: America is aging out. Seventy percent of the population age 65 and over will require long-term care at some point in their lives. Every day, 10,000 Americans turn 65. This is a huge population. And all of them have families who want to know how mom or dad is doing in long-term care. Complicating matters is the fact that many adult children do not live in the same city or town as mom and dad, which makes it harder to get information on their loved one.

    Another pain point is at the caregiver level. The workforce is under incredible stress. Turnover is huge. Workloads are heavy. There simply is no time to respond to all the requests they get for information, the need to share information, and also, to gather critical information such as consents. The long-term care industry, users and providers, needs a digital solution that improves communication, quality of care and relieves a huge burden from caregivers and administrators.

    BP: What is your value proposition?
    DW: Safekeeping’s How’s Mom platform is an automated, self-service family connection integrated with a long-term care or senior care center’s electronic health record (EHR) system. At the core of the solution is the How’s Mom Connections Hub that allows a facility to easily manage all family interactions such as share details on their clinical charts, document compliance with CMS communications rules within the EHR, communicate with families via text, email and the How’s Mom app, and automatically synch family contacts.Families have real-time, on-demand access to information they want and need about their loved one. They can schedule visits and receive notifications through the app. Patients also benefit from our platform.

    BP: Where are you in the commercialization process?
    DW: We are fully commercial and working on platform enhancements and functionality.

    BP: What’s your traction like thus far? Any barriers to sales?
    DW: We currently have 172 paying facilities in 32 states, with another 128 facilities actively participating or planning 30-day pilot programs. The biggest barrier to sales is the perception that IT implementations are difficult and time consuming. So there’s this cringe factor when people hear “software deployment.” The reality is our How’s Mom platform is nothing like that. Because we integrate with existing EHR systems – PointClickCare and MatrixCare as of today – implementation can be done in days with a minimum of effort. And truthfully, from our end, it takes less than an hour. The platform is very intuitive, so staff training is minimal. Families simply download the app and they’re live. That said, we offer 30-day free pilots to facilities so they can try it with no obligations.

    BP: COVID had a profound impact on nursing facilities and created fear and anxiety among families, patients and caregivers. How has it affected Safekeeping?
    DW: As you mentioned, COVID created anxiety among families especially in states that locked down long-term care facilities. The need for information on loved ones exploded when families could not visit in person. On the other side of the spectrum, facilities were under enormous pressure to stay staffed and create a safe environment for workers. Because of COVID, there has been tremendous turnover in staff such as nurses, social workers and particularly among CNAs. Add to that, new demands on staff time and no money to fund new protocols so we’ve seen long-term care facilities shut down as a result. So this is a stressed industry.

    Safekeeping has thrived under COVID because we remove communication and administrative burdens from staff and provide that critical, real-time connection point to information for families and loved ones.

    BP: The federal Cures Act is also working in your favor, correct?
    DW: Absolutely. This is an act passed in 2016 and is intended to give patients safe and secure access to health data so they can better manage their care and make more informed healthcare decisions. It was first implemented in hospitals and medical practices – you’ve likely used the portals hospitals now have on their websites – and now it is set to be implemented in long-term care facilities. Healthcare providers need to be ready to share certain electronic health records with patients and family members on request to be Cures Act compliant.

    Here’s the deal. While some of our clients are aware of the Cures Act and are specifically implementing our platform as their solution, many long-term care facilities are not aware they have to be compliant with the Act. Those not in compliance will face financial penalties in the form of lower reimbursements. As far as we know, Safekeeping, with our clinical focus and EHR integration, has the only platform that is Cures Act ready. Other apps will pop up, but this is not an easy integration. It will take at least 12 months, and probably longer, for a competitor to develop a solution.

    BP: Do you have any IP protection?
    DW: We are looking into patents and IP protection with our legal team. We do have it on our radar and likely will use a portion of funds from our next raise to begin the process.

    BP: Do you have competitors?
    DW: We do. Kind of. There are a number of companies focused on the social side of long-term care. They address social engagement, sharing photos and videos between mom and dad and their families. That’s the easy stuff. But it doesn’t solve anyone’s problems. Social apps make work for caregivers, add additional processes, and some require additional hardware and software—all of which are big turn-offs for senior care operators. 

    Safekeeping’s How’s Mom platform does the heavy lifting in terms of functionality and usability. Caregivers, families, and patients get a much richer, more complete experience in a self-serve format. Because we’re integrated with a facility’s EMR system, families can access information on their family member’s vitals, conditions, medications, and nutrition – the type of information people normally must call in to get.

    BP: How much are you planning to raise and what will the proceeds be used for?
    DW: This is a seed round and we’re hoping to raise $1 million to get us ready for a Series A raise. Half of this raise will go to continuing to add functionality to the platform that will drive adoption. The other half will go to sales and marketing. We just hired our first employee, a full-time salesperson, and customer support representatives will be added soon as well.

    BP: Why should VisionTech Angels invest in Safekeeping?
    DW: Four reasons. Founders who have personally lived the pain points of the industry and have a passion for delivering the right solution for caregivers, families and patients. Momentum in the industry; we’re integrated with the largest EHR company in the long-term care industry which provides instant credibility and ease of use. We’re market proven with nearly 200 users. And finally, timing is in our favor. Because of the Cures Act, long-term care facilities may soon be mandated to provide the type of information Safekeeping makes accessible now without adding any burdens to users.  I hope VisionTech investors go big.

    To learn more about Safekeeping, visit their website. VisionTech Angels’ August Pitch Events will be virtual on Tuesday, August 24 and Thursday, August  26 at 6 p.m. Pitch events are open to our members and accredited investors interested in joining our group. To register, check your email for an invitation, go to our Events page or email Ben Pidgeon at bpidgeon@visiontech-partners.com.

  • VisionTech Angels Invests $575,000 in Road Utility App OnStation, Leading Oversubscribed Seed Round of $1.4 Million

    VisionTech Angels Invests $575,000 in Road Utility App OnStation, Leading Oversubscribed Seed Round of $1.4 Million

    INDIANAPOLIS, Indiana (July 8, 2021) – – In the largest initial investment in the group’s 12-year history, VisionTech Angels have invested $575,000 in road construction productivity app OnStation, in a seed round that closed at $1.4 million. Cleveland, Ohio-based OnStation also has the distinction of being VisionTech Angels’ 50th portfolio company.

    VisionTech Angels led the round, with 53 of its investors participating. Joining VisionTech Angels in backing OnStation were HG Ventures, Indianapolis; Jumpstart, Cleveland; and Golden Angel Investors, Brookfield, Wisconsin. The round, which will be used to scale the company nationally, was oversubscribed by $400,000.

    VisionTech Executive Director Ben Pidgeon said the investment was significant on many levels. “Unlike a venture fund which writes one check, angel groups like VisionTech are composed of individual investors who decide whether or not to participate in a deal. Leading the investment round in OnStation with participation from this volume of members is a real achievement when the average check per VisionTech investor was just over $10,000. It came down to our investors having a lot of trust and confidence in OnStation’s Founder and Chief Technology Officer Jake Bailosky and CEO Patrick Russo.”

    Pidgeon adds, “We’re impressed with the current abilities of the product, the problems it solves for the road construction industry, customer feedback, market size, and growth potential.”

    The OnStation app, which enables better communications, productivity, and efficiency for road construction projects could not be better timed. On Thursday, July 1, the U.S. House of Representatives passed a $715 billion highway and water infrastructure bill that would direct $343 billion to highway and bridges infrastructure projects. The U.S. Senate is currently debating a $1.2 trillion infrastructure deal.

    While there’s no deal yet in Washington D.C., OnStation’s Russo says the company will primarily use the funding to scale the company, which is currently in use in 23 states. “We recently hired a growth marketer and civil technology engineer and have immediate plans to add sales professionals and additional developers so we can rapidly add more functionality to the app and automate the project onboarding process. Once a federal infrastructure bill is passed, we anticipate more states initiating roadway construction projects. Tools like OnStation will support better project management and greater productivity and efficiency to road construction teams. The volume of construction projects will make OnStation’s app essential to keep projects on track.” 

    OnStation is the brainchild of founder and CTO Bailosky who worked as a project engineer at the Ohio Department of Transportation (DOT) and who experienced first-hand the daily challenges of managing road construction projects. Bailosky also served on the Ohio DOT’s technology review board for four years and saw all of the tech solutions the agency was considering. He taught himself how to code and built the first generation of OnStation, the first jobsite productivity app that serves as a complementary plugin to larger road construction tech solutions.

    Today, OnStation is an industry leading application that brings better communication and efficiency to jobsites. Bailosky and Russo also credit JumpStart Cleveland, which mentored and supported the startup for four years, for much of their success to date. Over the last seven months, OnStation’s customer base is up seven-fold.

    Russo says it’s just a start. “We want to be on every jobsite and every road in the United States. And beyond!”

    About VisionTech
    Founded in 2009, VisionTech is a privately held company that links investors to high-potential, early-growth companies. Based in Indianapolis, VisionTech’s angel investing network includes more than 120 active members and chapters in Bloomington, Fort Wayne, Indianapolis, Lafayette, Indiana; and Dayton, Ohio. As of December 2020, 180 VisionTech members deployed more than $21.5 million in capital, investing in 50 portfolio companies from across the United States. Membership is open to accredited investors. Those interested in joining are encouraged to contact VisionTech.

    About OnStation
    OnStation is a highly collaborative mobile application created by PROJiTECH that empowers road construction workforces by supporting location-based documentation and communication across the entire project. This includes automatic location, access to project design files and contract documents, streamlined issue tracking, and group communication features. Through higher engagement and connectivity, OnStation enables more efficient jobsite workflow, keeping cones off the road, traffic flowing and work progressing. Learn more.

  • SonarMed’s Exit to Medtronic Is a Win for VisionTech Angels Investors and World’s Most Vulnerable Patients

    SonarMed’s Exit to Medtronic Is a Win for VisionTech Angels Investors and World’s Most Vulnerable Patients

    INDIANAPOLIS, Indiana (June 15, 2021) – –  Last month, when SonarMed announced it had been acquired by Medtronic, a global leader in medical technology, VisionTech Angels investors had much to celebrate. Ten years earlier, the group’s members were among the first to invest in the Carmel-based life sciences startup.

    Founded in 2005, SonarMed is the creator of the AirWave™ Airway Monitoring System that addresses critical airway management challenges, thereby addressing an enormous unmet need in premature infant, pediatric and adult patient populations in critical care, emergency departments and operating rooms. SonarMed’s technology was originally created as a graduate level project of Jeff Mansfield, M.D, SonarMed chief technology officer, and Eduardo Juan, M.D., at Purdue University. Medtronic has commercialized and is now marketing the technology.

    Angel investing is a high-risk game, particularly in the life sciences space where innovative technologies must meet stringent clinical and regulatory criteria before a commercial launch. VisionTech, like other angel investing groups, gets involved in early stage companies, providing capital and business advice and in the process, forming close relationships with company founders. SonarMed is one of the first investments made by VisionTech, which was founded in 2009.

    Managing Director Oscar Moralez explains what VisionTech Angels saw in the startup and their device. “As an Indiana-based angel network, we wanted to support regional innovation and particularly startups coming out of our research universities like Purdue. Our group also is attracted to life sciences startups.

    Moralez also had a personal interest. One of his children had been born three months prematurely, requiring a stay in a neonatal intensive care unit (NICU) to address breathing issues among other things. “I immediately connected to SonarMed and what their technology would mean for these high-risk babies and their families.”

    VisionTech Angels members made their first investment in SonarMed in 2010 and ultimately invested in multiple rounds over the next decade because of the belief the technology could help save lives.

    Tom Bumgardner, who served as CEO of SonarMed prior to the acquisition, explains the company’s AirWave Airway Monitoring System. “Our device is the only FDA-cleared airway monitoring system for patients like premature infants who can’t breathe on their own and truly challenges the status quo in critical care and anesthesia when used for detection of endotracheal tube movement, obstruction and placement. Clinicians using our device see better outcomes, which means fewer injuries, less time in the hospital, lower costs, and less heartache.”

    SonarMed also received early support from other high-profile Indiana investment groups, including Elevate Ventures, Indiana Economic Development Corporation and BioCrossroads. As the company and its technology progressed, other investors came on board at critical junctures: Hyde Park Angels, Baylor Angel Network, Central Texas Angel Network, Queen City Angels, and others. Nondilutive funding in the form of grants from the National Heart, Lung, and Blood Institute of the National Institutes of Health and the Indiana 21st Century Research and Technology Fund also contributed to the development of the AirWave device.

    Bumgardner acknowledges it “took a village” to elevate SonarWave and its technology. “We give a tremendous amount of credit to our early stage investors who took a leap of faith that our technology could change the course of airway management and that there was a market for it,” he said. “They stuck with us as mentors, advisors, and cheerleaders and never gave up.”

    Medtronic, with its extensive market presence, clinical leadership and market development expertise, was the ideal acquirer of SonarMed and the AirWave device, which is approved for use in the United States and the European Union. Medtronic is now actively rolling out the SonarWave device.

    VisionTech Angels has had three portfolio companies successfully exit over the last year. However, the SonarMed deal is particularly sweet for Moralez and VisionTech Executive Director Ben Pidgeon.

    “SonarMed is part of the VisionTech family; we literally grew up together, improving year by year,” Moralez says. “The financial reward of the exit is just part of it. Knowing we also played a role in supporting an innovative respiratory device that will help address a top patient safety issue for the most vulnerable patients,  premature infants through adults, around the world is the real ROI.”

  • Meet June Pitch Presenter #2: Ody, De La Paz CEO, Sensytec, Inc.

    Meet June Pitch Presenter #2: Ody, De La Paz CEO, Sensytec, Inc.

    While we were reviewing companies for June Pitch Week, a colleague at Lateral Capital, a micro VC in Sarasota, Florida, suggested VisionTech Angels take a look at Sensytec, a tech company out of Houston with a solution for the concrete industry. When I connected with the company’s CEO and Co-founder Ody De La Paz, he explained just how old school the concrete industry is and as a result, what a bottleneck and budget buster it’s become for the construction industry. Their solution is two-pronged, wireless real-time monitoring of concrete and an app that keeps a contractor’s fingers on the pulse of a job’s concrete, potentially saving a tremendous amount of time and money. The VisionTech Screening Committee and I invited Ody to present during our June Pitch Week. Here’s a sneak preview. I hope you’ll join us to hear Ody and participate in the discussion on this investment opportunity.

    BP: How did you get involved in the concrete industry?
    OD: I worked in the construction industry in my late teens and early 20s and found out quickly that working with concrete, specifically pouring and breaking test cylinders, was back-breaking work. I literally waited for the concrete trucks to come to the job site, they’d fill my wheelbarrow, I’d shovel the wet concrete into cylinders, wait for it to dry, and then break the cylinders to see if it had set correctly. It was time consuming and  like I said, back breaking!

    Later, as a student in the University of Houston’s entrepreneurship program, I met Anudeep Reddy, a civil and structural engineering student. He was working on a “smart cement” technology for monitoring the structural health of concrete and cement. I was intrigued. We started working together and in 2016 we co-founded Sensytec.

    BP: What pain point did you see in the market?
    OD: Concrete is a paint point for the construction industry. (Laughs) As complicated as it can be, the process of pouring, curing, and monitoring concrete is pretty much a guessing game. It’s largely reliant on manual tests that involve casting test cylinders, waiting for them to cure, and sending them to a lab to perform a break test. This is extremely time consuming. There are also many variables that can go wrong with concrete such as weather, the wrong mixture of water and cement and human error. During this last year, we’ve seen a labor shortage, causing more issues. Finally, problems with concrete can set a project back weeks and when a project goes past a deadline that costs money and contractors lose bonuses for meeting deadlines.

    Our solution, called SensyRoc™, is a wireless sensor that is embedded into the concrete as it’s poured. The sensor collects real-time data as the concrete cures, sending it wirelessly to our free mobile app where users, contractors, and their teams can instantly see and share what is happening with the concrete. Monitoring in place with Sensytec means no more cylinder tests are needed, less manual labor is needed and no waiting days for results. It’s all there on their smart phones when they need it, which is usually now. Time is money, and if you can save even a day on pouring, that’s significant. On average, we save contractors two days per pour on their projects, which equates to about $7,000- $10,000 a day.

    BP: That’s impressive. What kind of data are you tracking?
    OD: We’re tracking and monitoring a number of things like the in-place temperature of the concrete as that impacts the quality of the cure. We’re also tracking the setting time and compressive strength. And finally, the thing that really sets Sensytec apart is that we’re monitoring the electrical resistivity. When concrete is poured there can be voids, air pockets if you will, that won’t be detected by monitoring temperature alone. Electrical resistivity identifies the nature of voids. If there’s a problem, it can be addressed immediately and not weeks, months, or years down the road when it could become a structural or even liability issue. Electrical Resistivity also provides data on Hydration of concrete, water & cement ratio, and slump of concrete allows contractors to fully understand their concrete mix and better optimize their mix designs for their projects.

    BP: What kind of IP do you have?
    OD: We currently hold a worldwide patent on Smart cement technology and have a patent pending on SensyRoc that is intended to also be a worldwide patent. These patents are protecting the electrical resistivity measurements using embedded sensors in concrete, asphalt and other materials.

    BP: What kind of traction do you have?
    OD: We are commercial with our sensors in Texas, Oklahoma, Florida, Minnesota, and Iowa. Some of our customer are Flatiron, Meyer Contracting, Harvey Builders, and Silverstar Construction.

    BP: What is the competitive landscape?
    OD: There are competitors in this space. Hilti, which is a large supplier to the concrete industry, has a sensor solution. There’s also Giatec and Kryton that offer monitoring solutions. These products are all the same tech and only use temperature measurements. What sets us apart though is the electrical resistivity measurements. When concrete is poured, there can be voids, air pockets if you will, that won’t be detected by monitoring temperature alone. Electrical resistivity identifies the nature of voids. If there’s a problem, it can be addressed immediately and not weeks, months, or years down the road when it could become a structural or even liability issue. Electrical resistivity also provides data on hydration of concrete, the water and cement ratio. This allows contractors to fully understand their concrete mix and better optimize mix designs for their projects.

    BP: What is the potential for exit?
    OD:  Potential acquirers include large tool companies like DeWalt and Bosch that are adding to their technology solutions. RediMix, which is the leading concrete company in the U.S., is another potential acquirer.

    BP: What will this round be used for?
    OD: We are raising a $1 million seed round which we will use to expand outside of Texas, scale our manufacturing, and make key hires in sales, manufacturing and electrical engineering.

    BP: Why should VisionTech investors back you?
    OD: The concrete sector of the construction industry has tremendous room for improvement as it is still reliant on time-intensive manual processes. We believe there is a significant opportunity as our sensors and app will save contractors a tremendous amount of time and money. We are specifically looking for investors who bring more than capital and will serve more as partners in our growth and can potentially make introductions in the construction industry.

    To learn more about Sensytec, visit their website. VisionTech Angels’ June Pitch Events will be virtual on Tuesday, June 22 and Thursday, June 294at 6 p.m. Pitch events are open to our members and accredited investors interested in joining our group. To register, check your email for an invitation, go to our Events page or email Ben Pidgeon at bpidgeon@visiontech-partners.com.

  • Meet June Pitch Presenter #1: Jim Hussey, CEO, Seneca Therapeutics

    Meet June Pitch Presenter #1: Jim Hussey, CEO, Seneca Therapeutics

    Life sciences are a sweet spot for VisionTech Angels so when I met Jim Hussey, CEO of Seneca Therapeutics , at the ACA Life Sciences Syndicate meeting and learned about their virus that combats “cold” cancer tumors, I thought our group would be interested. Cancer therapeutics tend to be a long haul for investors, but Seneca is starting its Phase 2 trials of their lead asset, SVV-001, an oncolytic virus that shows significant clinical benefit in neuroendocrine tumors. Specifically, SVV-001 works to turn cold solid tumors hot and therefore treatable with immunotherapies. The VisionTech Screening Committee and I invited Jim to pitch during our June Pitch Week. Here’s a sneak preview. I hope you’ll join us to hear Jim and join in the discussion on this investment opportunity.


    BP: Seneca Therapeutics has a strong leadership and scientific team. Tell me about your founder, Paul Hallenback, and yourself.
    JH: We are really proud of the team we’ve assembled. Paul Hallenbeck is our founder, president and chief scientific officer. He’s spent the last 27 years in the biotechnology industry with tremendous expertise in all phases of cancer immuno-therapeutics R&D. Paul is also a serial entrepreneur and was the sole founder of Neotropix, where he raised $30 million in venture capital. Now with Seneca, Paul has led our lead asset, SVV-001, through IND approval and completed several Phase I/II clinical trials, establishing its safety and early evidence of efficacy. 

    I’ve spent my entire career in the pharmaceutical and biotech industries, the last 27 years in C-suite positions.  I left Morphosys—where I was president of the U.S. business—and joined Seneca because of the enormous upside of SVV-001. My focus is positioning Seneca for our Series B and ultimately an exit or partnership with big pharma with a highly favorable, near-term return for our investors.

    BP: I’m not an oncologist so please explain the issue here.
    JH: Certainly! Immunotherapy drugs are very effective on some types of cancers because they enable the body’s own T-cells to find and kill cancer cells. However, for these drugs to work, the tumor must be functional, hot and inflamed. The issue is many solid cancer tumors are cold and not inflamed so the immune system does not recognize them as foreign and does not attack the tumor. As a result, cold solid tumors do not respond to promising immunotherapies.

    There is a significant gap in the percentage of cancer patients who respond to immunotherapy. About 12.5% of tumors do respond and about 44% do not respond to the newer immunotherapies primarily because of cold tumors. So how do we enable the body’s immune system to get to work?  Oncolytic viruses like SVV-001 are unique in the ability to turn cold tumors hot and respond to immunotherapies like checkpoint inhibitors.

    Checkpoint inhibitors like Keytruda and Opdivo you’ve probably seen advertised are immunology drugs that work by blocking checkpoint proteins from binding with their partner proteins and sending an “all clear” message to the body. Using SVV-001, an oncolytic virus, the previously cold tumor is recognized as hot and the T cells do their job, which is attacking the cancer cells and allowing the checkpoint inhibitor to work.

    BP: What is novel about your lead asset, SVV-001?
    JH:  SVV-001 is small in size enabling rapid, potent, and efficient distribution and infection within tumors. This infection turns the tumor hot and leads to tumor cell death.  SVV-001 is a “best in class” oncolytic virus drug because of its “TEM8” advantage which makes it the most cancer-specific oncolytic virus. What TEM8 does is provide the opportunity to define the population where SVV-001 mediated therapy can make a major impact in terms of treatment response and outcomes. Due to the presence of TEM8 on more than 60% of solid tumors, we predict that more than 60% of patients may benefit. This would dramatically increase the number of patients with solid cancer tumors that respond to immunotherapy drugs.

    BP: What types of cancer is this best utilized for?
    JH: Ultimately, SVV-001 could be utilized in any type of solid tumors expressing TEM8 such as breast cancer, lung cancer and pancreatic cancer.  Seneca is currently focused on neuroendocrine tumors and neuroendocrine carcinoma.

    BP: What kind of IP do you have?
    JH: When the mechanism of action (binding to TEM8) for SVV-001 was discovered in 2017, it allowed new IP to be filed and issued through 2040.  There is other IP as well covering the gene delivery technology for SVV-001.

    BP: Where are you in the commercialization process?
    JH: We hope to file our BLA (biologics license application) with the FDA in the fourth quarter of 2023 and have this therapy on the market by second quarter 2024.

    BP: What does the market look like for an oncolytic virus like SVV-001?
    JH: The market for oncolytic virus platforms is robust with a tremendous amount of activity in the last three years and a lot of potential for additional exits. Some highlights include a $1 billion plus exit of BeneVir to Johnson & Johnson and a $900 million exit of Turnstone to Takeda. Both were pre-clinical, which says a lot about the level of interest. Here’s another—Replimune completed an IPO in July 2018 and now has a valuation of $1.6 billion and they’re currently in Phase II clinical trials. You also have Merck and Boehringer Ingelheim that have made acquisitions.

    BP: What will this round be used for?
    JH: We completed our Series A February 1 and are now raising a convertible bridge round leading into our Series B this fall. The bridge gives us additional time and flexibility as we plan the next round of Phase II and III clinical trials. The time and flexibility is for completing the animal data before we begin the clinical trial this fall and for negotiations with potential strategic pharma partners or VCs.  Our goal is to raise $5 million in our Series B and we have around $3 million left to raise.

    BP: Why should VisionTech investors back you?
    JH: The risk reward is very favorable. This is a later stage asset, with substantial human and animal data. We also have a ton of positive data from 76 humans who have received SVV-001 and that data supports the premise that SVV-001 solves the cold tumor issue. Turning cold tumors hot and therefore receptive to immunotherapies is a significant development for patients whose tumors were previously not responding to immunotherapies.

    To learn more about Seneca Therapeutics, visit their website. VisionTech Angels’ June Pitch Events will be virtual on Tuesday, June 22 and Thursday, June 294at 6 p.m. Pitch events are open to our members and accredited investors interested in joining our group. To register, check your email for an invitation, go to our Events page or email Ben Pidgeon at bpidgeon@visiontech-partners.com.

  • Meet April Pitch Week Presenter #2: Lindsay Watson, CEO of Augment Therapy

    Meet April Pitch Week Presenter #2: Lindsay Watson, CEO of Augment Therapy

    If you’re a parent or grandparent, you know how much kids love computer games. When Pittsburgh’s BlueTree Venture Fund suggested VisionTech look at Augment Therapy, a startup that has “gamified” the children’s physical therapy sector, I was immediately interested. How do you gamify something like physical therapy? The company’s CEO, Lindsay Watson, explained that her software platform is designed to engage kids in therapy they often don’t want to do in a way that’s fun. Even kids with the most challenging medical conditions enjoy it. The VisionTech Screening Committee and I were impressed, so we invited Lindsay to present during April Pitch Week. Here’s a sneak preview. I hope you’ll join us for our virtual pitch events on Tuesday, April 27 at 6 p.m. and Thursday, April 29 at 6 p.m. Registration information is at the end of this post.

    BP: Tell me a little about yourself and how you went from physical therapist to entrepreneur.
    LW: Early in my life, I knew I wanted to go into medicine. I chose physical therapy because I thought it would allow more balance for a career and family. I was obsessed with helping kids so for the next 17 years, I was a pediatric physical therapist working in hospitals, clinics and schools. About five years ago, I realized there had to be a better way to provide services. With adults, you can hand them a piece of paper with ten exercises they need to do and they’ll do it (most of the time). Kids are very different. They are motivated by technology. I became fixated on how I could use digital tools to entice them to do their physical therapy. For example, what if I could use Pokémon Go, an augmented reality game, to get them to walk. Ultimately, I came up with a software platform that combined augmented reality, telemedicine, and remote patient care with gamification and launched my company, Augment Therapy, four years ago.

    BP: What inspired you to found Augment Therapy?
    LW: The traditional way of delivering physical therapy to kids creates pretty profound pain points. Let me give you an example. A child with Down’s syndrome develops their gross motor skills development much more slowly. Pediatricians order physical therapy starting around age two. This requires parents to bring their child to a clinic every week for years. This is incredibly hard for families. They expend all of their energy getting their child to therapy, working on it at home, and coming back for the next round. Seeing this repeated with each family, I felt it was so wrong.

    The other side of the coin is the pain kids feel. They can be scared of their therapist, scared that the exercises will hurt, or in the case of Down’s syndrome kids, be stubborn and just not participate. There had to be a better way.

    BP: How did you know you were on the right track?
    LW: I don’t often share this story but I was about a year into the company when my four-year-old daughter developed septic arthritis and had to have emergency surgery on her hip. We were in the hospital with her for a week. She had to have intense physical therapy. It was so painful she’d scream when the therapist came into her room. My software was still rudimentary but when we got home, my daughter became my first test patient. She loved it! She wasn’t afraid because it was like playing. That was when Augment Therapy went from obsession to my life’s purpose. I realized I’d been doing physical therapy wrong for 20 years.

    BP: Fast forward a couple of years. What does Augment Therapy look like today?
    LW: First, the company has really benefitted from participating in a number of accelerators, including the Plug and Play Accelerator in Cleveland, KidsX (the first pediatric-focused digital health accelerator in the world) and the MassChallenge HealthTech. The exposure to mentors, other startups, and investors has been fantastic and helped fine-tune our offering.

    Today, Augment Therapy is truly an all-in-one solution to engage, motivate, and monitor kids needing therapeutic exercise. It’s designed for therapists to use in-clinic, via telehealth, or as a new tool for home exercise program monitoring. We’ve built and continue to build a library of evidence-based exercises and interactive games using augmented reality. Another valuable feature is data collection; behind the scenes we capture step counts, repetitions, hand movements, duration, and other metrics are collected with no wearable sensors required. We also provide usage logs, including session start and end time plus time on task to support billing and reimbursement—and that’s a big one particularly for telemedicine. Augment Therapy is also HIPAA and COPPA compliant.

    BP: What’s your revenue model?
    LW: Monthly subscriptions that includes unlimited patients and sessions and for use in-clinic, telehealth, and home exercise program prescription and monitoring. We currently charge hospital enterprise customers $60,000 per year for two departments with up to 25 providers; private practice outpatient clinics pay $350/month for up to five providers; and individual therapists pay $50 a month. 

    BP: Has COVID impacted your business?
    LW: I hate to say it, but when the pandemic hit—BOOM! In a matter of weeks, all of the barriers we had were wiped away. Clinics and therapists needed a new way to deliver services that was socially distance, reimbursable and effective. We checked all boxes. It was great knowing our product kept kids on track with their therapy.

    BP: How big is the market?
    LW: In 2018, the U.S. outpatient physical, occupational, and speech therapy centers sector was estimated at $34.5 billion. The pediatric therapy sector is much smaller, and represents 8% of that or roughly $2.8 billion.  Despite this smaller size, there are many reasons why this market is an attractive entry point. First, this niche has a profound unmet need and true pain point for parents and kids who typically receive therapy care for years on end versus the average adult who is in therapy for three to six months.  The pediatric market has few solutions directed at solving their problems despite the fact that they are some of its long-term consumers.  Our niche offering makes Augment Therapy an attractive acquisition for a larger company focused on the adult sector. 

     BP: Who are your competitors?
    LW: Although we do have competitors, there is no one doing the exact same thing in our space. Most are focused on the adult market. Some offer telemedicine only, others engagement options. We are the only company that is engagement, telemedicine, augmented reality, and gamification for all settings, inpatient, outpatient and home.

    BP: What kind of traction are you seeing?
    LW: We have a lot on our plate!  We have a pilot program with University Hospitals’ Rainbow Babies & Children’s Hospital in Cleveland and are signing a three-year contract. We are finalizing two deals with educational services companies in Ohio that provide physical therapy services in schools. We are also scoping five pilots, three in the U.S. and two overseas, with hospitals through the KidsX Accelerator and two more through Mass Challenge Health Tec in a Midwest hospital system that spans two states. We’ll also be announcing a major collaboration on April 22 that I’m really excited about.

    BP: What will this investment round be used for?
    LW: We’re raising $1.25 million and of this, we’ve already closed on $902,500. The funds will be used to add to our team to help execute our pilot programs. This includes hiring another developer and operations team members.

    BP: Why should VisionTech investors back you?
    LW: The main reason is that we’re going to change a lot of lives for the better. From a business perspective, we are strategically well positioned for the seismic shift in healthcare due to COVID-19 that accelerated, literally overnight, adoption of telemedicine and digital health solutions. Because of our pilot programs and collaboration opportunities, our valuation is going to go up quickly. There is a lot of interest in who’s going to close the round and we’re really looking for investors who bring more to the table than checks.

    To learn more about Augment Therapy, visit their website. VisionTech Angels’ April Pitch Events will be virtual on Tuesday, April 27 and Thursday, April 29 at 6 p.m. Pitch events are open to our members and accredited investors interested in joining our group. To register, check your email for an invitation, go to our Events page or email Ben Pidgeon at bpidgeon@visiontech-partners.com.